sLAG-3 in non-small-cell lung cancer patients’ serum

BACKGROUND: Anti-programmed cell death-1/programmed cell death ligand-1 monoclonal antibodies have been widely used in non-small-cell lung cancer (NSCLC), but not every patient can get benefits from them. Whether other molecular markers can predict the results of programmed cell death-1/programmed c...

Full description

Saved in:
Bibliographic Details
Published in:Onco Targets Ther
Main Authors: He, Yayi, Wang, Yan, Zhao, Sha, Zhao, Chao, Zhou, Caicun, Hirsch, Fred R
Format: Artigo
Language:Inglês
Published: Dove Medical Press 2018
Subjects:
Original Research
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6097502/
https://ncbi.nlm.nih.gov/pubmed/30147330
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S164178
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items